: The inability to efficiently repair DNA double-strand breaks using the homologous recombination repair pathway is defined as homologous recombination deficiency (HRD). This molecular phenotype represents a positive predictive biomarker for the clinical use of poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors and platinum-based chemotherapy in ovarian cancers. However, HRD is a complex genomic signature, and different methods of analysis have been developed to introduce HRD testing in the clinical setting. This review describes the technical aspects and challenges related to HRD testing in ovarian cancer and outlines the potential pitfalls and challenges that can be encountered in HRD diagnostics.

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches / Mangogna, Alessandro; Munari, Giada; Pepe, Francesco; Maffii, Edoardo; Giampaolino, Pierluigi; Ricci, Giuseppe; Fassan, Matteo; Malapelle, Umberto; Biffi, Stefania. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 13:2(2023), p. 284. [10.3390/jpm13020284]

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

Francesco Pepe;Pierluigi Giampaolino;Umberto Malapelle;
2023

Abstract

: The inability to efficiently repair DNA double-strand breaks using the homologous recombination repair pathway is defined as homologous recombination deficiency (HRD). This molecular phenotype represents a positive predictive biomarker for the clinical use of poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors and platinum-based chemotherapy in ovarian cancers. However, HRD is a complex genomic signature, and different methods of analysis have been developed to introduce HRD testing in the clinical setting. This review describes the technical aspects and challenges related to HRD testing in ovarian cancer and outlines the potential pitfalls and challenges that can be encountered in HRD diagnostics.
2023
Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches / Mangogna, Alessandro; Munari, Giada; Pepe, Francesco; Maffii, Edoardo; Giampaolino, Pierluigi; Ricci, Giuseppe; Fassan, Matteo; Malapelle, Umberto; Biffi, Stefania. - In: JOURNAL OF PERSONALIZED MEDICINE. - ISSN 2075-4426. - 13:2(2023), p. 284. [10.3390/jpm13020284]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/913406
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact